Watch the interview of Dr. Pourhassan naming Montefiore Medical Center... Video

Pipeline

Building a Broad Pipeline of
Indications

Mechanism of Action: Leronlimab as a CCR5 antagonist

Program Indication Pre-clinical Phase 1 Phase 2 Phase 3
HIV
Combination Therapy 1
Pre-clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress
Monotherapy 2
Pre-clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress
Cancer
Triple-Negative Breast 3
Pre-clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Basket trial for 22 solid tumors
(Including melanoma, brain-glioblastoma, throat, lung, stomach, colon, breast, testicular, ovarian, uterine, pancreas, bladder, among other indications)
Pre-clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Immunology
GvHD 4
Pre-clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
NASH 5
Pre-clinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Coronavirus [COVID-19] 6
Pre-clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Autoimmune (mutiple potential indications including Crohn's disease, IBS (inflammatory bowel syndrome), MS (Multiple Sclerosis), Hashimoto's thyroiditis, Vasculitis, Psoriasis, Polymyositis, Autoimmune Hepatitis, Grave's disease, Sjogren's syndrome, Myasthemia gravis)
Pre-clinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
  1. BLA filing in-process, 1/3rd complete
  2. Protocol for pivotal Phase 3 trial filed
  3. Trial underway with Fast Track designation
  4. Trial underway with Orphan Drug designation
  5. IND and Phase 2 protocol filed
  6. Patient treatment underway via Emergency IND; Phase 2 trial protocol filed

Licensing Opportunities

Mechanism of Action: Proprietary gene sequencing, A.I.

Program Indication 510(k)
Prognostic
Prostate Cancer 1
510(k) Phase in progress
  1. In discussions and seeking 510(k)

Leronlimab for HIV Treatment

Our lead product, Leronlimab (PRO 140), is the world’s first self-injectable, subcutaneous injection for HIV and has many advantages over the current standard of care, HAART, including no serious side effects, enhanced compliance, and longer half-life.

Read More on Leronlimab

Leronlimab for Cancer Metastasis

Recent research demonstrated the importance of CCR5 in cancer indications and indicates that Leronlimab (PRO 140) is a potential inhibitor of the CCR5 receptor.

Read More on CCR5

Mitigating Acute GVHD with Leronlimab

Graft-versus-host disease (GVHD) is a serious complication that limits the use of Bone Marrow Stem Cell (BMSC) transplantation in patients with blood cancers. Our current clinical trial studies Leronlimab for the prevention of GVHD in patients (RIC) undergoing BMSC transplantation.

Read More on GVHD

PCa Test for Accurate Prostate Cancer Diagnosis

Our PCa Test is an unbiased and valuable tool to provide guidance to assist the physician and prostate cancer patient to make a more informed decision regarding a potentially life-altering surgery based on their true risk profile.

Read More on PCa Test

Get In Touch

For more information on Leronlimab, our science, or our new developments, please reach out to us using the link provided.

Ask a Question